EntryPoint Capital’s Xeris Biopharma Holdings XERS Stock Holding History

EntryPoint Capital’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$558K	Buy	96,210 +28,127	+41%	+$186K	0.16%	209
2025 Q4	$534K	Buy	68,083 +15,068	+28%	+$119K	0.21%	141
2025 Q3	$432K	Sell	53,015 -19,884	-27%	-$132K	0.17%	222
2025 Q2	$340K	Sell	72,899 -2,807	-4%	-$12.9K	0.17%	227
2025 Q1	$416K	Buy	75,706 +22,946	+43%	+$92.6K	0.19%	173
2024 Q4	$179K	Buy	52,760 +18,127	+52%	+$58.3K	0.08%	610
2024 Q3	$98.7K	Buy	+34,633	New	+$88.9K	0.06%	557
2024 Q2	–	Sell	-3,963	Closed	-$8.76K	–	1703
2024 Q1	$8.76K	Buy	+3,963	New	+$10.3K	0.01%	1256

Other funds holding XERS

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT)

Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $244M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return